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RAPID COMMUNICATION
Monocyte chemoattractant protein 1 mediates glomerular
macrophage infiltration in anti-GBM Ab GN
WINs0N W. TANG, MEIYING Qi, and JEFFREY S. WARREN
Department of Anatomic Pathology, Amgen Inc., Thousand Oaks, California, and Department of Pathology, University of Michigan Medical Schoo4 Ann
Arbor, Michigan, USA
Monocyte chemoattractant protein 1 mediates glomerular macrophage
infiltration in anti-GBM Ab GN. Monocyte chemoattractant protein 1
(MCP-1) is a C-C chemokine with potent monocyte chemotactic and
activating properties that may contribute to glomerular macrophage
infiltration in anti-GBM Ab UN. We have previously reported increased
glomerular steady state expression of MCP-i mRNA relative to GAPDH
mRNA in the heterologous phase of experimental anti-GBM Ab GN. In
this report, we expand upon these data by demonstrating that the increase
in MCP-1 mRNA correlated with MCP-i protein expression at 24 hours
that was determined with an ELISA (2069 147 pg/mg glom lysate). This
increase in MCP-1 expression was associated with glomerular monocyte/
macrophage infiltration which peaked at 24 hours (8.2 1.0 ED-i
cells/glom). The Site of MCP-1 mRNA production was localized by
combining immunohistochemistry with in situ hybridization. The majority
of cells which expressed MCP-i mRNA at three hours were intrinsic
glomerular cells, while 55% of the cells that expressed MCP-i mRNA at
15 hours were monocytes/macrophages. To determine if MCP-1 affected
glomerular macrophage infiltration, rats with a-GBM Ab GN were
administered a polyclonal neutralizing Ab to rat MCP-i. This resulted in
a 38% decline in glomerular macrophage infiltration (3.3 0.3 vs. 1.8
0.2 ED-i cells/glom, P = 0.0001) that was associated with a 45% reduction
in urinary protein excretion (260 53 vs. 162 46 mg/d, P = 0.0001).
These data demonstrate an important role for MCP-i in the pathogenesis
of glomerular macrophage infiltration in anti-GBM Ab GN.
Macrophages are important effector cells mediating injury in
anti-glomerular basement membrane (GBM) antibody (Ab) as-
sociated glomerulonephritis (GN) [1]. The mechanisms whereby
macrophages induce glomerular injury remains incompletely un-
derstood but include the generation of reactive oxygen species [2],
cytokines including interleukin-1 (IL-i) and tumor necrosis factor
(TNF) [3], eicosanoids [4], collagenases and proteases [5]. Al-
though a cell resembling the mononuclear phagocyte exists within
the normal glomerular mesangium [6], macrophages infiltrating the
glomerulus in anti-GBM Ab GN are believed to result from
the recruitment of peripheral blood monocytes. Monocytes within
the circulation migrates into areas of inflammation in response to
chemotattractants such as complement [7], neutral lipids [8],
leukotrienes [9], platelet activating factor [10] and chemokines
[reviewed in 11, 121.
Chemokines are a superfamily of proteins of molecular mass 8
to 10 kDa that are important in recruiting and activating leuko-
cytes during inflammation [11, 12]. Two subfamilies have been
described, a and /3, based upon the arrangement of the first two
cysteines. The a chernokines have been shown to attract and
activate granulocytes. By comparison, the 13 subfamily affects
primarily monocytes although recent studies suggest they can also
activate lymphocytes, basophils and eosinophils [11, 12]. A mem-
ber of the /3 subfamily, monocyte chemoattractant protein I
(MCP-1), is of particular interest since it is a potent monocyte
chemotactic and activating factor [13]. In addition to chemotaxis,
MCP-1 up-regulates the leukocyte /32 integrins, CDIIb and
CD1Ic, and stimulates IL-i [141, superoxide anion and hydrogen
peroxide production (15].
Several a chemokines including macrophage inflammatory
protein (MIP)-2, platelet factor 4, interferon-inducible protein 10
kDa (IP-lO), and cytokine-induced neutrophil chemoattractant
(CINC) have been demonstrated to precede neutrophil influx in
experimental anti-GBM Ab GN [16—18]. A similar role has been
suggested for the /3 chemokines, MCP-i and MIP-la, in the
pathogenesis of glomerular macrophage infiltration in anti-GBM
Ab GN [16, 19]. Previous studies with neutralizing Abs have
shown that inhibition of CINC or MIP-2 activity decreases
glomerular neutrophil infiltration 40 to 50%, which is associated
with attenuation of proteinuria in anti-GBM Ab GN (16—18]. In
contrast, the contribution of the /3 chemokines to macrophage
infiltration in this disease remains uncertain.
To understand the role of the /3 chemokines in the induction of
immune glomerular injury, we studied the expression of MCP-1 in
the heterologous phase of experimental anti-GBM Ab GN in the
rat. The glomerular expression of MCP-i in this model at 24 hours
was quantitated with an ELISA. The site of MCP-1 mRNA
expression within the glomerulus was localized by combining in
situ hybridization with immunohistochemistry. In addition, the
effect of MCP-i on glomerular monocyte/macrophage infiltration
was studied by administering a polyclonal neutralizing Ab. These
data demonstrate an important role for MCP-1 in the pathogen-
esis of glomerular macrophage infiltration in anti-GBM Ab GN.
Methods
Experimental model
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Normal rabbit serum (NRS) was obtained by bleeding naive
unimmunized rabbits while a-GBM Ab was prepared by immu-
nizing New Zealand white rabbits with rat GBM as previously
described [201. Both the cs-GBM Ab serum and NRS were
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decomplemented and absorbed with lewis rat erythrocytes. Twen-
ty-seven Lewis rats (Charles River Lab, Wilmington, MA) were
injected with 0.5 ml of either a-GBM Ab (N = 18) or NRS (N =
9) intravenously. Three rats with anti-GBM Ab GN were eutha-
nized at the following time points: 30 minutes, 3, 6, 9, 15 and 24
hours. Control rats were euthanized at 30 minutes, 6 and 24 hours.
Twenty-four hour urine was collected from control and anti-GBM
Ab GN rats at the latter time point. In addition, 3 female Lewis
rats were injected with a-GBM Ab and euthanized at 24 hours for
the determination of MCP-i protein expression. Glomeruli
(>90% purity) were isolated on a #200 mesh screen by sequen-
tial sieving through #60 and #100 mesh wire screens. The
glomeruli were lysed in PBS and frozen at —70°C until assayed.
Morphologic studies
Renal tissue was fixed in 10% formalin for light microscopy and
immunohistochemistry. Histologic sections were stained with the
periodic acid-Schiff reaction and hematoxylin counterstain. Im—
munohistochemistry was performed on deparaffinized sections
that were incubated with a murine monoclonal Ab to rat mono-
cyte/macrophage, ED-i (Harlan Bioproducts for Science, Inc.,
Indianapolis, IN, USA). Clone ED-I was detected using horse-
radish peroxidase ABC reagents from BioTek (Santa Barbara,
CA, USA) with DAB as the chromagen. Glomerular monocyte/
macrophage infiltration was determined by counting the number
of cells expressing ED-i in 25 consecutive glomeruli with similar
cross section diameters. Data are presented as the mean sum of
variances.
Immunohistochemist.'y!in situ hybridization
The preparation of the rat MCP-i riboprobe has been de-
scribed previously [16]. Sense and anti-sense MCP-i riboprobes
were prepared by in vitro transcription with SF6 and T7 RNA
polymerase, respectively, and the incorporation of 33P-UTP (New
England Nuclear, Boston, MA, USA). Immunohistochemistry
with the ED-I monoclonal Ab was performed on deparrafinized
sections (3 to 5 /xm) as described above. The slides were then
digested with proteinase K, and hybridized overnight with the
33P-UTP labeled sense and antisense MCP-i riboprobes at 50°C.
After successive washes with increasing stringency, the slides were
dipped in Kodak NTB2 emulsion and exposed at 4°C for three
weeks. The slides were developed at 15°C in Kodak D19, fixed,
and then counterstained with hematoxylin and eosin.
Determination of glomerular MCP-1 production
Glomeruli lysate from rats that had been administered a-GBM
Ab 24 hours prior to sacrifice were added to microtiter plates that
had been coated with Abs to rat MCP-1 (BioSource International,
Camarillo, CA, USA). The captured MCP-1 was then incubated
with a biotinylated second Ab that was then detected with
strepavidin-peroxidase and diaminobenzidine. The optical density
at 450 nm was determined on a Thermomax microplate reader
(Molecular Devices, Menlo Park, CA, USA). A reference curve
was generated from known concentrations of recombinant rat
MCF-1 which was assayed in parallel. Samples were assayed in
triplicate and data are presented relative to the protein concen-
tration present within each sample which was determined by the
Bio-Rad protein assay (Bio-Rad Lab, Richmond, CA, USA). The
assay has been shown not to cross react with rat MIP-2, IFN-y, or
TNF-cr.
Neutralization studies
The preparation and characterization of the affinity purified
rabbit a-rat-MCF-i Ab has been described previously [21].
Briefly, New Zealand white rabbits were immunized against the 23
kDa recombinant rat MCP-1 rat species emulsified in Hunters'
Titermax (CytRx, Norcross, GA, USA). a-rat MCF-i IgG and
nonspecific rabbit IgG were affinity purified with protein G
Sepharose 4B (Pharmacia) and contained < 0.012 nglml of
endotoxin activity as estimated by the Limulus amebocyte lysate
assay (E-toxate, Sigma). The a-rat MCP-i IgG reacts specifically
with the 18 kDa, 21 kDa, and 23 kDa forms of recombinant rat
MCP-1 on Western blotting and neutralizes monocyte chemotaxis
induced by the 23 kDa MCP-i species. Female Lewis rats were
injected with either 100 xg of rabbit anti-rat MCP-i Ab (N = 12)
or an equivalent concentration of affinity purified rabbit IgG (N =
12) 5 to 10 minutes before a-GBM Ab administration. A different
a-GBM Ab was used for these experiments than had been used in
the previous time course study. The rats were placed in a
metabolic cage for urine collection and euthanized at 24 hours.
Twenty-four-hour urinary protein excretion was determined by
the sulfosalicylic acid method with rat albumin (Sigma) serving as
the standard.
Quantitiation of a-GBM Ab binding
To insure that the a-MCP-1 Ab did not interfere with the
binding of the a-GBM Ab, an ELISA was developed to quantitate
glomerular binding of the latter Ab. Glomeruli from the kidneys
of rats in the neutralization study were isolated by sequential
sieving as described above and lysed in i% SDS by sonification.
The glomerular lysate was plated onto a 96 well EIAJRIA flat
bottom plate (Costar Corp., Cambridge, MA, USA) overnight at
4°C. After blocking with 1% bovine serum albumin/5% sucrose in
TRIS/EDTA, the plate was incubated with horseradish peroxidase
conjugated swine a-rabbit IgG (DAKO Inc., Carpinteria, CA,
USA) at 25°C for one hour, washed with 0.02% Tween 20, and
then developed with hydrogen peroxide and 3,3',S,S'-tetramethyl-
benzidine for iS minutes. The reaction was quenched with
phosphoric acid and the optical density at 450 nm was determined
on a Thermomax microplate reader (Molecular Devices). A
reference curve was generated from known concentrations of
affinity purified rabbit IgG (Jackson ImmunoResearch, West
Grove, PA, USA) that was assayed in parallel. Samples were
assayed in triplicate and data were presented relative to the
protein concentration present within each sample which was
determined by the Bio-Rad DC protein assay.
Statistical methods
Data are presented as the mean SD. Statistical analyses were
performed by comparing individual group means using the un-
paired Student's t-test. A P < 0.05 was considered significant.
Results
Morphology
The glomerular pathology of the 27 rats used for the time
course study (0.5 to 24 hr) has been described previously [16].
Briefly, there was a diffuse infiltrative GN composed of primarily
PMNs following the induction of anti-GBM Ab GN which peaked
at three hours (20.8 ii.i PMN/glom). The PMN infiltration was
followed by monocyte/macrophage infiltration with 2.6 0.6
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Fig. 1. Autoradiograph of a RNase protection assay demonstating increased MCP-1 steady state mRNA expression relative to GAPDH mRN.4 0.5, 3, 6, 9,
15 and 24 hours after induction of a-GBM .4b GN (+). Control rats (-) which had received NRS were sacrificed at 0.5, 6 and 24 hours.
ED-I cells/glom at six hours, 7.1 1.2 ED-i cells/glom at 15
hours, and peaked at 8.2 1.0 ED-i cells/glom at 24 hours.
In situ hybridization
A temporal profile of glomerular MCP-1 mRNA expression in
these rats has been previously described and is presented in
Figure 1 [16]. Briefly, there was a ninefold increase in MCP-1
steady-state mRNA expression relative to GAPDH mRNA 30
minutes after induction of anti-GBM Ab GN. The increased
MCP-i mRNA expression peaked at i5 hours (24-fold) and was
only fivefold greater than control rats by 24 hours (Fig. 1). Based
upon the results of this data, in situ hybridization was performed
on the kidneys of rats with anti-GBM Ab GN euthanized at 3 and
15 hours. There was strong glomerular labeling with the anti-sense
MCP-1 riboprobe 3 and 15 hours after a-GBM Ab administration.
The number of cells that hybridized with the anti-sense riboprobe
increased from 3 to 15 hours, which is consistent with the
temporal profile of glomerular MCP-1 expression.
In an attempt to characterize the cell(s) that were expressing
MCP-1 mRNA, in situ hybridization was performed on kidney
sections labeled with ED-i. At three hours, it could be seen that
the majority of cells which expressed MCP-i mRNA did not label
with ED-i identifying them as intrinsic glomerular cells (Fig. 2A).
At the periphery of occasional glomeruli, epithelial cells can be
confidently seen to express MCP-1 mRNA. In contrast, by 15
hours, 55% of the cells which hybridized with the MCP-i anti-
sense riboprobe were monocytes/macrophages (Fig. 2B). The
labeling was specific since the anti-sense MCP-i riboprobe did not
hybridize with the glomeruli of control (NRS treated) rats (Fig.
2C) while the sense MCP-1 riboprobe did not hybridize with
nephritic glomeruli at 15 hours (Fig. 2D).
Determination of glomerular MCP-1 production
The increased expression of MCP-1 mRNA correlated with
increased expression of the protein as determined by an ELISA
specific for rat MCP-1. In rats with anti-GBM Ab GN at the 24
hours time point, the concentration of MCP-1 within isolated
glomeruli was 2069 147 pg/mg glomerular lysate.
Neutralization studies
The role of MCP-i in the pathogenesis of glomerular mono-
cyte/macrophage infiltration in a-GBM Ab GN was assessed by
administering a MCP-1 neutralizing lgG. There was a 38%
decline in glomerular macrophage infiltration (1.8 0.2 ED-i
cells/glom) when compared with rats which had received rabbit
IgG (3.3 0.3 ED-i cells/glom, P = 0.0001). This was accompa-
nied by a 45% decrease in the 24-hour urinary protein excretion
(162 46 vs. 260 53 mg/day, P = 0.0001). The administration
of the anti-MCP-1 IgG did not affect the binding of the a-GBM
Ab (0.52 0.04 xg/mg glom lysate) when compared with rats that
had received rabbit IgG (0.48 0.04 xg/mg glom lysate). Simi-
larly, the anti-MCP-1 IgG did not affect the number of monocytes
within the peripheral circulation (0.15 0.05 X i03/pJ) when
compared with control rats (0.11 0.04 x i0/j1i).
Discussion
The present study demonstrates a role for the C-C chemokine,
MCP-i, in the pathogenesis of macrophage infiltration in heter-
ologous phase a-GBM Ab GN. We have previously reported a
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ninefold increase in glomerular MCP-1 mRNA 30 minutes after
induction of anti-GBM Ab GN [161. The mRNA expression
peaked at 15 hours and preceded the peak of macrophage
infiltration at 24 hours. The temporal appearance of MCP-1
mRNA relative to glomerular macrophage infiltration suggest a
role for this chemokine in recruiting macrophages into the
glomerulus. This study expands upon these observations by dem-
onstrating that the MCP-1 mRNA is indeed translated into
protein.
These data are consistent with previous work demonstrating
increased expression of MCP-1 in anti-GBM Ab GN and in
mesangioproliferative GN [19, 22]. In the anti-Thy I model, Stahl
et a! reported an approximate threefold increase in MCP-1
expression 30 minutes after induction of GN which returned to
control values by 24 hours followed by a lesser increase at 5 and
21 days [22]. Similarly, Rovin et a! reported increased MCP-I
mRNA expression 90 minutes after induction of a-GBM Ab GN
which peaked within the first 24 hours, a temporal profile that is
consistent with the present data [19]. However, neither study
demonstrated a causal role for MCP-1 in the pathogenesis of
glomerular macrophage infiltration. The present study expands
upon the work of these previous investigators by demonstrating
that the administration of anti-rat MCP-1 IgG decreased glomer-
ular monocyte/macrophage infiltration 38% at 24 hours that was
associated with a 45% reduction in urinary protein excretion.
The incomplete protection afforded by neutralization of MCP-1
activity is not surprising given the multiplicity of chemokines that
are expressed in the heterologous phase of anti-GBM Ab GN. We
have previously shown that the steady state expression of MIP-la
and IP-lO mRNAs peaks within three hours of anti-GBM Ab
administration and remains elevated through 24 hours [16].
Although an a chemokine, IP-lO is a chemoattractant for acti-
vated T-cells and monocytes and is the only member of the the a
subfamily not to attract PMNs [23—25]. Indeed, we have noted an
association of IP-lO expression with tubulointerstitial macrophage
infiltration in puromycin aminonucleoside GN (manuscript in
preparation). These data suggest that simoultaneous inhibition of
multiple chemokines will be required for suppression of glomer-
ular inflammation.
The mechanism by which inhibition of MCP-1 activity results in
attenuation of proteinuria is likely multifactorial. In addition to
chemoattraction, MCP-i induces macrophage adhesion by up-
regulating the expression of the /32 integrins, CD11b and Cdllc
[26, 27]. MCP-1 may also exacerbate inflammation by stimulating
monocyte/macrophage to produce IL-i, hydrogen peroxide, su-
peroxide anion and releasing lysosomal enzymes [27, 28]. There-
fore, inhibiting one or more of these proinfiammatory effects
likely accounts for the reduction in proteinuria achieved with
neutralization of MCP-1.
The site of MCP-1 production in anti-GBM Ab GN is of
interest since MCP-1 is produced by numerous cell types including
endothelial cell [29], vascular smooth muscle cell [30], fibroblast
[31], activated neutrophil [32], and monocyte/macrophage [33].
Within the kidney, both mesangial cells [34] and renal cortical
epithelial cells [35] have been shown to produce MCP-1. By
combining immunohistochemistry with in situ hybridization on
kidney sections from rats with evolving anti-GBM Ab GN, a
biphasic pattern of MCP-1 mRNA expression was discerned.
Glomerular MCP-1 mRNA expression early in the course of
anti-GBM Ab GN (3 hr) was limited to primarily intrinsic
glomerular cells. Glomerular epithelial cells could be confidently
identified as expressing MCP-i mRNA in occasional sections.
Unfortunately, attempts at immunolabeling glomerular endothe-
hal cells with a rabbit Ab to Factor VIII was hindered by cross
reactivity with the anti-GBM Ab. With progression of anti-GBM
Ab GN (15 hr), MCP-1 mRNA was localized within both intrinsic
glomerular cells and infiltrating monocytes/macrophages. These
data suggest that MCP-1 functions as both a paracrine (early in
the course of anti-GBM Ab GN) and autocrine chemokine.
Although not a primary goal in the design of this study, the
mechanism(s) that controls MCP-1 expression warrants comment.
In preliminary experiments, we have found that IL-ira adminis-
tration produces a 21% reduction in MCP-1 mRNA expression
three hours after induction of GN. These results are consistent
with in vitro data in which IL-i stimulates MCP-1 production by
fibroblast, endothelial and mesangial cells [36—38] while IL-ira
inhibits mesangial cell MCP-1 production [39]. IL-ira has been
previously shown to attenuate glomerular macrophage infiltration
in heterologous phase a-GBM Ab GN [20]. In addition to IL-i,
other cytokines including TNF and y-interferon also up-regulates
MCP-1 expression [36—38]. Interestingly, thrombin which is gen-
erated within the glomerulus in anti-GBM Ab GN also stimulates
MCP-i production by mesangial cells [3, 40]. Similarly, monocyte
adhesion to P-selectin present on platelets and endothelial cells
increases PAF induced MCP-i secretion [41]. A role for P-
selectin in the early phase of anti-GBM Ab GN has been
previously reported [42]. Finally, VCAM-1, whose monocyte
counterreceptor, the integrin a4B1 has been shown to be impor-
tant in the pathogenesis of a-GBM Ab GN may also regulate
MCP-i production [43, 44].
Glomerular macrophage infiltration in anti-GBM Ab GN is a
complicated process which remains incompletely understood.
One possible paradigm, based upon the results of this and
previous studies, involves the binding of the anti-GBM Ab to the
GBM with activation of complement. C5a, in addition to being a
chemotaxin, induces rapid translocation of P-selectin to the
glomerular endothehial surface [45] where it can interact with
sialyl Lewis-X carbohydrate residues on macrophages. This serves
to decrease the transit velocity of the macrophage as well as
induce PAF stimulated secretion of MCP-1 and TNF-a. In
addition, C5a induces IL-i production by monocytes [46]. Con-
currently, intrinsic glomerular cells also produce IL-i and TNF
which can induce endothehial MCP-1 expression. In turn, IL-i and
TNF activates the coagulation cascade which has been shown to
induce MCP-1 production by mesangial cells. The resultant
MCP-i will attract monocytes to the glomerulus and promote
their adhesion to ICAM-1 present on the endothelium by up-
regulating CDiib and Cdllc expression. Finally, MCP-1 will
stimulate macrophage production of oxidants, cytokines including
IL-i and TNF which will feed back into the cascade, and proteases
damaging the GBM resulting in proteinuria.
In conclusion, the present study demonstrates an important role
for MCP-1 in the pathogenesis of monocyte/macrophage infiltra-
tion in anti-GBM Ab GN. The clinical relevance of these findings
is suggested by the localization of MCP-1 within the nephritic
glomeruhi of patients with crescentic GN, Wegener's granuloma-
tosus, and systemic lupus erythematosus [19]. However, the lack
of complete protection afforded by the anti-rat MCP- 1 Ab suggest
a role for other chemokines and is consistent with the redundancy
present within the chemokine family. The incomplete protection
670 Tang et al: MCP-1 expression in cx-GBM Ab GN
noted in the present study when assessed in light of similar results
achieved by neutralizing CINC and MIP-2 suggest that a thera-
peutic strategy targeted at chemokines will require antagonist
which can suppress multiple chemokines simoultaneously.
Reprint requests to Winson W Tang, M.D., Amgen Inc., 1840 DeHavilland
Drive, MS15-2-A-250, Thousand Oaks, California 91320, USA.
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